$11.65 -$0.35 (-2.9%)

04:30 PM EDT on 04/03/20

Corcept Therapeutics, Inc. (NASDAQ:CORT)

CAPS Rating: 3 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Current Price $11.65 Mkt Cap $1.3B
Open $12.00 P/E Ratio 14.14
Prev. Close $11.65 Div. (Yield) $0.00 (0.0%)
Daily Range $11.57 - $12.49 Volume 1,113,571
52-Wk Range $9.70 - $14.96 Avg. Daily Vol. 1,333,297

Caps

How do you think NASDAQ:CORT will perform against the market?

Add Stock to CAPS Watchlist

All Players

85 Outperform
26 Underperform
 

All-Star Players

12 Outperform
5 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CORT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

vistacarolina (29.76)
Submitted March 31, 2017

Great Co. will see positive results.

zzlangerhans (99.74)
Submitted July 13, 2016

In medicine we generalists have a saying: When you only tool is a hammer, every problem becomes a nail. It refers to the propensity of specialists to interpret every problem through the lens of their specialty. If a patient comes in with syncope, the… More

Recent Community Commentary

Read the most recent pitches from players about CORT.

Recs

0
Member Avatar jed71 (99.91) Submitted: 2/19/2020 8:57:54 AM : Outperform Start Price: $13.25 NASDAQ:CORT Score: +14.47

It's extremely hard to deny that Corcept has delivered on financial results quarter after quarter for several years. Their gross margins are incredible and I continue to marvel at the fact that the stock remains a good value in this market. They have boatloads of cash on the sidelines and quite a few up and coming phase trials this year that should yields some exciting results. I have never been the best at selecting pharmas, but this one appears to be a good stub to put a marker on in Caps. I haven't bought yet, but am looking forward to listening to their conference call tomorrow prior to making any real life decisions.

Recs

0
Member Avatar MarkBiotech (< 20) Submitted: 3/7/2018 6:03:49 PM : Outperform Start Price: $15.75 NASDAQ:CORT Score: -17.13

Corcepts lead product korlym is expected to lose exclusivity in 2019.. although that seems concerning.. it isnt.. the small market size in CS will prevent price wars for when generics do enter into the market.. also, Relacorilant, an improved product for CS will EASILY replace Korlym.. Relacorilant will make korlym and any other generic competitors in the space absolete.. Relacorilant is also being explored in clinical trials in combination with abraxane for solid tumors.. Management has expressed that early results have been promising.. If solid tumor data results are as good as managements optimism, we can see CORT fly well above what it is currently worth.. Management are also exploring other combo therapies including korlym in TNBC, CORT125281+xtandi in CRPC.. Also CORT118335 for NASH shouldn't be taken out of the picture.. since their pipeline are all in early stages of development, CORT is considered a speculative play in the favor of longs. the preliminary data of Relacorilant is robust(despite low N) and was executed with the low-end dose.. a higher dose should prove to have better efficacy... Abraxane as a stand alone agent for solid tumors has shown to work in LC,TNBC, CRPC.. the problem with early clinical combo therapies(W/O single agent data), is that sometimes it is hard to figure out whether the net effect is from the combo or from the standalone agent. regardless this confusion of benefit from the combo should boost CORT's share price as market investors are incompetent of realizing the difference between solo efficacy vs combo efficacy.. (see nktr-214).

Recs

0
Member Avatar aeroberts831 (< 20) Submitted: 3/5/2018 9:18:29 PM : Outperform Start Price: $14.68 NASDAQ:CORT Score: -11.77

Teva ANDA announcement of Corcept's lead product Korlym tanked stock 40%, but Teva will not bring to market a generic formulation of Korlym with any meaningful effect on Corcept's revenues.

Leaderboard

Find the members with the highest scoring picks in CORT.

Score Leader

thiscoloradokid

thiscoloradokid (< 20) Score: +590.92

The Score Leader is the player with the highest score across all their picks in CORT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
thiscoloradokid < 20 12/5/2012 12/4/2013 Outperform 3M $1.52 +666.45% +75.53% +590.92 0 Comment
alvojiggy 83.08 10/23/2013 Outperform 5Y $1.73 +573.41% +41.95% +531.46 0 Comment
GOGCwatch07 < 20 9/18/2013 Outperform 5Y $1.73 +573.41% +45.11% +528.30 0 Comment
FinanceGuy58 60.48 12/9/2013 7/24/2015 Outperform 3Y $2.01 +481.05% +36.90% +444.14 0 Comment
wgrohman < 20 3/21/2013 Outperform 3Y $1.94 +500.52% +60.35% +440.17 0 Comment
HoosierDoozer < 20 12/5/2013 Outperform 5Y $2.06 +465.53% +38.31% +427.22 0 Comment
loangolfer < 20 1/10/2013 11/14/2019 Outperform NS $1.96 +494.08% +69.22% +424.86 0 Comment
HoldThatWinner 30.55 3/11/2013 Outperform 1Y $2.00 +482.50% +59.76% +422.74 0 Comment
cavemantrader 30.55 11/29/2013 Outperform 5Y $2.10 +454.76% +36.86% +417.90 1 Comment
rserafini 63.55 3/25/2013 Outperform 5Y $2.04 +471.08% +59.06% +412.02 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CORT.